Introduction
Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related death in developed countries, is a lethal disease with an overall 5-year survival rate of <5% [1] . Due to the paucity of early symptoms, along with aggressive tumor behavior, less than 20% of patients present localized and resectable diseases at the time of diagnosis, and standard therapies only have a limited beneficial impact on advanced-stage patients [2] . Currently, attempts are being made to identify novel biomarkers to diagnose and predict PDAC outcome.
We have previously described lpha-enolase (ENOA) as a tumor-associated antigen (TAA) in PDAC [3] . ENOA is a moonlighting protein that works both as a glycolytic enzyme and as a membrane plasminogen receptor, thus promoting tumor proliferation, spreading and metastasis [4, 5] . In particular, a fraction of PDAC patients specifically produce autoantibodies against two Ser 419 phosphorylated isoforms of ENOA (ENOA1,2), which are over-expressed in PDAC [3, 4, 6, 7] . The detection of autoantibodies against ENOA1,2 positively complements the diagnostic performance of the commonly used serum marker CA19.9. Moreover, patients with autoantibodies against ENOA1,2 have a more favorable clinical course, with a longer progression-free and overall survival rate upon gemcitabine treatment [3] .
A variety of post-translational modifications of naturally processed peptides displayed by MHC class I or II molecules have recently been described [8] . Among the post-translationally modified peptides identified to date, phosphopeptides are of particular interest, as deregulated phosphorylation is one of the major hallmarks of malignant transformation. T cell discrimination of phosphopeptides versus their unphosphorylated counterparts has also been observed, indicating that phosphorylation can influence peptide immunogenicity [9, 10, 11, 12] . Depending on the position within the peptide, phosphorylation tends to stabilize the complex, without greatly altering the peptide-binding mode.
The prognostic value of autoantibodies to ENOA1,2, together with the ability of ENOA to induce a specific CD4 + T cell response, led us to investigate whether the ability to produce autoantibodies against ENOA1,2, in PDAC patients, is associated with specific HLA-DRB1 alleles. Here, we demonstrate that expression of the HLA-DRB1*08 allele is greater in PDAC patients with autoantibodies to ENOA1,2 compared to healthy controls or patients lacking these antibodies. We found that a bioinformatically-predicted Ser 419 phosphorylated-ENOA peptide, which binds with high affinity to the HLA-DR8 molecule coded by HLA-DRB1*08:01 or *08:04 alleles, was able to activate in vitro proliferation of specific CD4 + T cell clones derived from a HLA-DRB1*08:01 donor. P-ENOA, and T cells were then cloned for limited dilution, as previously described [15] . Long term CD4 + T cell clones were re-stimulated every 10-14 days with irradiated feeder cells. 
Materials and Methods

Human samples.
Generation of
Results
HLA-DRB1 allelic frequencies in PDAC patients and production of autoantibodies to ENO1,2.
The presence of circulating autoantibodies to the PDAC-associated ENOA1,2 isoforms was assessed by 2-DE WB in 113 PDAC patient sera, using CF-PAC-1 cell lysates as source of antigen.
The HLA-DRB1 allelic frequencies of the same patients were in parallel analyzed with low resolution methods. 
Prediction of possible HLA ligands of the ENOA C-terminus.
High resolution typing of HLA-DRB1*08 PDAC patients (n=9) showed that 89% of patients were HLA-DRB1*08:01 or *08:04 (n=8/9; relative frequencies: 67% and 22%, respectively), Figure 1) .
Specific CD4
+ T cell recognition of the Ser 419 P-ENOA peptide.
Since the four N-terminal residues in positions P4 to P1 of the binding core of a tumor-associated PBMCs from a HLA-DRB1*08:01 healthy donor were repeatedly stimulated in vitro with the Ser 419 P-ENOA peptide. In long-term CD4 + T cell cultures, 21 CD4 + T cell clones were selected, which were able to proliferate in response to the autologous EBV-B cells pulsed with Ser 419 P-ENOA (data not shown). Five of these CD4 + T cell clones showed a significant proliferative response to the Ser 419 P-ENOA, which was higher than that induced by the unphosphorylated peptide (Figure 2A) . Moreover, using increasing concentrations of the Ser 419 P-ENOA peptide for pulsing of autologous EBV-B cells, a dose-dependent proliferation of CD4 + T cell clones was observed ( Figure 2B ). These data indicate that CD4 + T cells specifically recognize Ser 419 P-ENOA, demonstrating that the phosphorylated serine residue is a critical determinant of recognition.
Discussion
In this study we demonstrate, for the first time, an association between the presence of the HLA-DRB1*08 allele and the production of autoantibodies against a phosphorylated epitope of a specific [19, 20] . ENOA in PDAC can elicit a coordinated CD4 + and CD8 + T cell response both in vitro and in vivo and, in PDAC patients, the production of anti-ENOA IgG correlates with the ability of T cells to be activated in response to ENOA [21] . Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes has revealed that ENOA Th1/Th17 effector cells and T reg cells tend to accumulate in tumor tissue [15] .
The prognostic value of Ser 419 P-ENOA-autoantibodies, together with the ability of ENOA to induce a specific CD4 + T cell response, prompted us to investigate whether, in PDAC patients, the ability to produce autoantibodies against Ser 419 P-ENOA is associated with the presence of specific HLA-DRB1 alleles. Here we show that the allelic frequency of HLA-DR8, coded by the HLA-DRB1*08:01 or *08:04 alleles, was significantly higher in PDAC patients with ENOA1,2 autoantibodies than in patients without autoantibodies or in healthy controls, suggesting a preferential presentation of Ser 419 P-ENOA peptides by HLA-DR8.
The ENOA sequence shows several bioinformatically-predicted HLA-DR8 binding peptides, and the ability of ENOA-derived peptides to bind HLA-DR8 has also been previously reported in primary biliary cirrhosis and in oral squamous cell carcinoma [22, 23, 24, 25] . Interestingly, the Cterminus region of ENOA that contains Ser 419 was predicted to bind with high affinity to the HLA-DR8 molecule, with the residue Ser 419 in position P3 of the HLA-DR8 binding peptide. As the phosphomoiety stabilizes the MHC class II-TCR complex, without altering the peptide-binding mode when it is not present in a primary or secondary anchor [17] , the same peptide is likely to be able to bind HLA-DR8 when the phosphorylation event occurs. This Ser 419 phosphorylated peptide was synthesized according to the molecular basis for phosphopeptide MHC class II presentation, recently resolved by crystallographic analysis, and was able to activate specific CD4 + T cell clones derived from a HLA-DRB1*08:01 donor. Synthetic peptides were chosen as Ser 419 -ENOA phosphorylation seems to be pancreatic specific [3, 18] , suggesting that ENOA would not be properly phosphorylated when expressed into EBV-transformed cells. As reported in previous studies in which T cells could discriminate phosphopeptides from their unphosphorylated counterparts [9, 10, 11, 12] , the HLA-DR8-restricted CD4 + T cell clones were specific for the phosphate moiety of the ENOA-derived peptide presented in the context of HLA-DR8. The crystal structure of phosphopeptide-MHC complexes shows, in fact, that the phosphomoiety is exposed to the TCR, suggesting a direct interaction between the phosphorylated residue and the TCR [8, 17, 26] .
The identification of a CD4 + T cell clone able to proliferate and produce IFN-γ after stimulation with ENOA-derived phosphopeptide strongly supports the hypothesis that the preferential production of IgG antibodies to Ser 419 P-ENOA in HLA-DR8 patients is critically controlled by the activation of CD4 + helper T cells that recognize the phosphopeptide in the context of HLA-DR8. It is likely that this ENOA-derived phosphopeptide is displayed by the HLA-DRB1*08 allele on the surface of B cells or other APCs and thus activates specific CD4 + T helper cells, which in turn help B cells to produce antibodies against this tumor-associated ENOA-derived phosphopeptide.
Although the frequency of the HLA-DRB1*08 allele is relatively low in Caucasian populations, its presence could be considered as a genetic factor that influences the production of autoantibodies against ENOA1,2.
In conclusion, our results suggest that Ser -419 P-ENOA peptide-MHC complexes can trigger T-cell signaling and induce an anti-tumor immune response, thus portraying ENOA not only as a diagnostic tool, but also as a promising candidate for PDAC immunotherapy. DNA-based vaccination against human ENOA is able to significantly prolong the median life expectancy of mice that spontaneously develop PDAC, by inducing both a humoral and cellular response [27] .
Based on the findings described in this study, together with the prognostic value of Ser 419 P-ENOAautoantibodies, it can be speculated that the presence of HLA-DRB8 in PDAC patients can be an indicator of a better response to chemotherapy, as well as a potential marker for selecting candidates for DNA-based ENOA vaccination. classified according to ENOA1,2 reactivity (n=104; described in Supplementary Table 1) , and healthy controls (n=260801). HLA-DR8 was significantly more frequent in PDAC patients with autoantibodies to ENOA1,2 than in healthy controls (8% vs. 3%, p=0.0112, allelic frequency) and is higher than in PDAC patients lacking these autoantibodies (8% vs. 2%, allelic frequency). 
